Skip to main content
OpenTrials

Clinical trial condition

PIK3CA Mutation

Explore clinical trials studying PIK3CA Mutation. Study availability and eligibility vary by location and protocol.

5 public trials 4 recruiting studies
Refine in advanced search Browse all conditions

PIK3CA Mutation trial results

Recruiting

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

NCT07524322

Conditions
Adnexal Diseases, Advanced Breast Cancer, Breast Cancer, +30 more
Locations
  • START Los Angeles Los Angeles, California, United States
  • The University of Texas MD Anderson Cancer Center Houston, Texas, United States
  • NEXT Houston Houston, Texas, United States
  • NEXT San Antonio San Antonio, Texas, United States
View Trial Details
Recruiting

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

NCT06982521

Conditions
Advanced Breast Cancer, Breast Cancer, Breast Diseases, +9 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Beverly Hills Cancer Center Beverly Hills, California, United States
  • City of Hope National Medical Center Duarte, California, United States
  • Cedars-Sinai Medical Center Los Angeles, California, United States
View all 211 locations
View Trial Details
Recruiting

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)

NCT06789913

Conditions
Angiomatosis, CLOVES Syndrome, Cardiovascular Abnormalities, +17 more
Locations
  • Phoenix Children's Hospital Phoenix, Arizona, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • University of California, Los Angeles Los Angeles, California, United States
  • Stanford University Palo Alto, California, United States
View all 34 locations
View Trial Details
Recruiting

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

NCT05216432

Conditions
Advanced Breast Cancer, Breast Cancer, Breast Diseases, +10 more
Locations
  • The University of Arizona Cancer Center Tucson, Arizona, United States
  • University of California-San Diego San Diego, California, United States
  • HealthONE Denver, Colorado, United States
  • Yale University New Haven, Connecticut, United States
View all 37 locations
View Trial Details
Completed

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

NCT05759949

Conditions
Advanced Breast Cancer, Breast Cancer, Breast Diseases, +11 more
Locations
  • Sarah Cannon Research Institute at Florida Cancer Specialists Orlando, Florida, United States
  • Community Cancer Center North Indianapolis, Indiana, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States
View Trial Details

Related conditions